Impairment loss on fixed assets in the Pharmaceuticals segment
First written in FY2020-Q2. 4 of 10 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Re-recognition of impairment lossesAnnual report
「Because undiscounted future cash flows from the asset fell below its carrying amount as a result of changes in business conditions and other factors, the carrying amount was reduced to its recoverable amount, and the decrease was recorded as an impairment loss under extraordinary losses.」
The Pharmaceuticals segment recorded an impairment loss of ¥843 million on long-term prepaid expenses. The asset subject to the loss and the amount were updated from the impairment loss recorded in the previous fiscal year. - FY2024-Q3RestatedAnnual report
「Not applicable.」
The company stated that no impairment loss on fixed assets was recorded in the Pharmaceuticals segment for the nine-month period ended the third quarter of the current fiscal year. - FY2024-Q2RestatedAnnual report
「Not applicable.」
The company reconfirmed that no impairment loss on fixed assets was recorded in the Pharmaceuticals segment for the six-month period ended the second quarter of the current fiscal year. - FY2024-Q1DroppedAnnual report
「Not applicable.」
The company stated that no impairment loss on fixed assets was recorded in the Pharmaceuticals segment for the three-month period ended the first quarter of the current fiscal year. - FY2023-Q3RestatedAnnual report
「The Pharmaceuticals segment recorded an impairment loss. The impairment loss recorded amounted to ¥304 million for the nine-month period ended the third quarter of the current fiscal year.」
The recording of a ¥304 million impairment loss on fixed assets in the Pharmaceuticals segment has continued to be disclosed from the first and second quarters of the previous fiscal year. - FY2023-Q2RestatedAnnual report
「The Pharmaceuticals segment recorded an impairment loss. The impairment loss recorded amounted to ¥304 million for the six-month period ended the second quarter of the current fiscal year.」
The recording of a ¥304 million impairment loss on fixed assets in the Pharmaceuticals segment has continued to be disclosed from the first quarter of the previous fiscal year. - FY2023-Q1Re-recognition of impairment lossesAnnual report
「The Pharmaceuticals segment recorded an impairment loss. The impairment loss recorded amounted to ¥304 million for the three-month period ended the first quarter of the current fiscal year.」
The company recorded a ¥304 million impairment loss on fixed assets in the Pharmaceuticals segment. The impairment loss on fixed assets in the Pharmaceuticals segment, which had disappeared from the disclosures after being recorded previously, is shown again. - FY2021-Q2DroppedAnnual report
「Not applicable.」
The company stated that no impairment loss on fixed assets was recorded in the Pharmaceuticals segment for the six-month period ended the second quarter of the current fiscal year. The ¥266 million recorded for the six-month period ended the second quarter of the previous fiscal year is no longer disclosed for the current period. - FY2020-Q3Higher amount recognizedAnnual report
「The Pharmaceuticals segment recorded an impairment loss. The impairment loss recorded amounted to ¥287 million for the nine-month period ended the third quarter of the current fiscal year.」
The amount of the impairment loss on fixed assets in the Pharmaceuticals segment was updated from ¥266 million for the six-month period ended the second quarter to ¥287 million for the nine-month period ended the third quarter. - FY2020-Q2First statedAnnual report
「The Pharmaceuticals segment recorded an impairment loss. The impairment loss recorded amounted to ¥266 million for the six-month period ended the second quarter of the current fiscal year.」
The company first disclosed that it recorded a ¥266 million impairment loss on fixed assets in the Pharmaceuticals segment for the six-month period ended the second quarter of the current fiscal year.